Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats

Prometheus：快速开发针对新兴病毒威胁的基于人类抗体的治疗和预防方法的平台

• 批准号: 10088385
• 负责人: Kartik Chandran
• 金额: $ 439.05万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-02-14 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10088385
• 关键词: Academia; Advanced Development; African; Americas; Andes Virus; Antibodies; Antibody Therapy; Blood specimen; Categories; Collaborations; Complement; Crimean-Congo Hemorrhagic Fever Virus; DNA; Data; Development; Disease; Disease Outbreaks; Ebola virus; Engineering; Epitopes; Etiology; Europe; Evaluation; FDA approved; Generations; Goals; Government; Half-Life; Hantavirus; Hantavirus Pulmonary Syndrome; Hemorrhagic Fever with Renal Syndrome; Human; Immunity; Individual; Industry; Infection; Injections; Lead; Mediating; Modeling; Monoclonal Antibodies; Nairovirus; National Security; Natural Immunity; Pharmaceutical Preparations; Production; Prophylactic treatment; Proteins; Public Health; Recombinants; Research Personnel; Resistance; Risk; Rodent; Rodent Model; Russia; Sin Nombre virus; Survivors; Technology; Therapeutic; Treatment Efficacy; Vaccines; Variant; Viral; Virus; Virus Diseases; Work; World Health Organization; Zaire Ebola virus; Zoonoses; base; cost; efficacy study; high risk; human monoclonal antibodies; in vivo; innovation; natural antibodies; neutralizing monoclonal antibodies; nonhuman primate; pathogenic virus; prophylactic; protective efficacy; public health emergency; side effect; standard of care; success; synergism; therapeutic candidate

The overarching goal of the Prometheus CETR is to discover and develop human antibody-based prophylactics and therapeutics against two major groups of Category A priority viruses that cause severe zoonotic disease—the nairovirus Crimean-Congo hemorrhagic fever virus (CCHFV), and the hantaviruses Andes virus (ANDV), Sin Nombre virus (SNV), and Puumula virus (PUUV). CCHFV, ANDV, and SNV are Category A agents that pose the highest risk to national security and public health. In their latest annual review, the World Health Organization designated CCHF as a Blueprint Priority Disease with the greatest potential to cause a public health emergency. There are no approved vaccines or treatments for any of these agents. The Prometheus CETR, an interwoven collaboration among seven partners from academia, government, and industry organized into two projects and three cores, will accomplish two Grand Goals that are each aimed at delivering a therapeutic product against our target viral pathogens. We will develop and deliver: (1) an antibody-based therapeutic with broad efficacy against CCHFV; and (2) an antibody-based therapeutic with broad efficacy against the hantaviruses ANDV and SNV.

The overarching goal of the Prometheus CETR is to discover and develop human antibody-based prophylactics and therapy against two major groups of Category A priority virus that causes severe zoonotic disease—the nairovirus Crimean-Congo hemorrhagic fever virus (CCHFV), and the hantaviruses Andes virus (ANDV), Sin Nombre virus (SNV), and Puuumula virus (PUUV). CCHFV，ANDV和SNV是对国家安全和公共卫生构成最高风险的代理类别。在其最新的年度审查中，世界卫生组织将CCHF指定为蓝图优先疾病，其可能会引起公共卫生紧急情况。这些药物中的任何一个均无批准的疫苗或治疗方法。 Prometheus Cetr是学术界，政府和行业的七个合作伙伴之间的交织合作，分为两个项目和三个核心，将实现两个宏伟的目标，旨在针对我们的目标病毒病原体提供治疗产品。我们将开发和交付：（1）基于抗体的治疗，对CCHFV具有广泛的效率； （2）一种基于抗体的治疗，对汉坦病毒和V和SNV具有广泛的效率。